204 related articles for article (PubMed ID: 24615332)
1. Identification of cellular and genetic drivers of breast cancer heterogeneity in genetically engineered mouse tumour models.
Melchor L; Molyneux G; Mackay A; Magnay FA; Atienza M; Kendrick H; Nava-Rodrigues D; López-García MÁ; Milanezi F; Greenow K; Robertson D; Palacios J; Reis-Filho JS; Smalley MJ
J Pathol; 2014 Jun; 233(2):124-37. PubMed ID: 24615332
[TBL] [Abstract][Full Text] [Related]
2. Tip30 controls differentiation of murine mammary luminal progenitor to estrogen receptor-positive luminal cell through regulating FoxA1 expression.
Chen F; Li A; Gao S; Hollern D; Williams M; Liu F; VanSickle EA; Andrechek E; Zhang C; Yang C; Luo R; Xiao H
Cell Death Dis; 2014 May; 5(5):e1242. PubMed ID: 24853420
[TBL] [Abstract][Full Text] [Related]
3. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
[TBL] [Abstract][Full Text] [Related]
4. Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity.
Van Keymeulen A; Lee MY; Ousset M; Brohée S; Rorive S; Giraddi RR; Wuidart A; Bouvencourt G; Dubois C; Salmon I; Sotiriou C; Phillips WA; Blanpain C
Nature; 2015 Sep; 525(7567):119-23. PubMed ID: 26266985
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.
Prat A; Parker JS; Karginova O; Fan C; Livasy C; Herschkowitz JI; He X; Perou CM
Breast Cancer Res; 2010; 12(5):R68. PubMed ID: 20813035
[TBL] [Abstract][Full Text] [Related]
6. RUNX1, a transcription factor mutated in breast cancer, controls the fate of ER-positive mammary luminal cells.
van Bragt MP; Hu X; Xie Y; Li Z
Elife; 2014 Nov; 3():e03881. PubMed ID: 25415051
[TBL] [Abstract][Full Text] [Related]
7. Alterations of EGFR, p53 and PTEN that mimic changes found in basal-like breast cancer promote transformation of human mammary epithelial cells.
Pires MM; Hopkins BD; Saal LH; Parsons RE
Cancer Biol Ther; 2013 Mar; 14(3):246-53. PubMed ID: 23291982
[TBL] [Abstract][Full Text] [Related]
8. Reproductive history determines Erbb2 locus amplification, WNT signalling and tumour phenotype in a murine breast cancer model.
Ordonez LD; Melchor L; Greenow KR; Kendrick H; Tornillo G; Bradford J; Giles P; Smalley MJ
Dis Model Mech; 2021 May; 14(5):. PubMed ID: 34003256
[TBL] [Abstract][Full Text] [Related]
9. Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.
Prat A; Karginova O; Parker JS; Fan C; He X; Bixby L; Harrell JC; Roman E; Adamo B; Troester M; Perou CM
Breast Cancer Res Treat; 2013 Nov; 142(2):237-55. PubMed ID: 24162158
[TBL] [Abstract][Full Text] [Related]
10. Claudin expression in high-grade invasive ductal carcinoma of the breast: correlation with the molecular subtype.
Lu S; Singh K; Mangray S; Tavares R; Noble L; Resnick MB; Yakirevich E
Mod Pathol; 2013 Apr; 26(4):485-95. PubMed ID: 23222490
[TBL] [Abstract][Full Text] [Related]
11. The cell of origin of BRCA1 mutation-associated breast cancer: a cautionary tale of gene expression profiling.
Molyneux G; Smalley MJ
J Mammary Gland Biol Neoplasia; 2011 Apr; 16(1):51-5. PubMed ID: 21336547
[TBL] [Abstract][Full Text] [Related]
12. p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin.
Megha T; Ferrari F; Benvenuto A; Bellan C; Lalinga AV; Lazzi S; Bartolommei S; Cevenini G; Leoncini L; Tosi P
J Clin Pathol; 2002 Jun; 55(6):461-6. PubMed ID: 12037031
[TBL] [Abstract][Full Text] [Related]
13. [Expression of PTEN, p53 and EGFR in the molecular subtypes of breast carcinoma and
the correlation among them].
Li X; Wang Q; Fu L; Liu M; Yu X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2015 Sep; 40(9):973-8. PubMed ID: 26408616
[TBL] [Abstract][Full Text] [Related]
14. Dysregulated PTEN-PKB and negative receptor status in human breast cancer.
Shi W; Zhang X; Pintilie M; Ma N; Miller N; Banerjee D; Tsao MS; Mak T; Fyles A; Liu FF
Int J Cancer; 2003 Mar; 104(2):195-203. PubMed ID: 12569575
[TBL] [Abstract][Full Text] [Related]
15. Reprogramming of the estrogen responsive transcriptome contributes to tamoxifen-dependent protection against tumorigenesis in the p53 null mammary epithelial cells.
Palaniappan M; Edwards D; Creighton CJ; Medina D; Conneely OM
PLoS One; 2018; 13(3):e0194913. PubMed ID: 29590203
[TBL] [Abstract][Full Text] [Related]
16. TOX3 is expressed in mammary ER(+) epithelial cells and regulates ER target genes in luminal breast cancer.
Seksenyan A; Kadavallore A; Walts AE; de la Torre B; Berel D; Strom SP; Aliahmad P; Funari VA; Kaye J
BMC Cancer; 2015 Jan; 15():22. PubMed ID: 25632947
[TBL] [Abstract][Full Text] [Related]
17. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer.
Tamimi RM; Baer HJ; Marotti J; Galan M; Galaburda L; Fu Y; Deitz AC; Connolly JL; Schnitt SJ; Colditz GA; Collins LC
Breast Cancer Res; 2008; 10(4):R67. PubMed ID: 18681955
[TBL] [Abstract][Full Text] [Related]
18. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.
Fernandes RC; Bevilacqua JL; Soares IC; Siqueira SA; Pires L; Hegg R; Carvalho FM
Histopathology; 2009 Sep; 55(3):346-52. PubMed ID: 19723150
[TBL] [Abstract][Full Text] [Related]
19. Prolactin cooperates with loss of p53 to promote claudin-low mammary carcinomas.
O'Leary KA; Rugowski DE; Sullivan R; Schuler LA
Oncogene; 2014 Jun; 33(23):3075-82. PubMed ID: 23873024
[TBL] [Abstract][Full Text] [Related]
20. Phenotypic and functional characterisation of the luminal cell hierarchy of the mammary gland.
Shehata M; Teschendorff A; Sharp G; Novcic N; Russell IA; Avril S; Prater M; Eirew P; Caldas C; Watson CJ; Stingl J
Breast Cancer Res; 2012 Oct; 14(5):R134. PubMed ID: 23088371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
